Mibefradil: Difference between revisions

	WikiDoc Resources for Mibefradil
Articles
Most recent articles on Mibefradil Most cited articles on Mibefradil Review articles on Mibefradil Articles on Mibefradil in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mibefradil Images of Mibefradil Photos of Mibefradil Podcasts & MP3s on Mibefradil Videos on Mibefradil
Evidence Based Medicine
Cochrane Collaboration on Mibefradil Bandolier on Mibefradil TRIP on Mibefradil
Clinical Trials
Ongoing Trials on Mibefradil at Clinical Trials.gov Trial results on Mibefradil Clinical Trials on Mibefradil at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mibefradil NICE Guidance on Mibefradil NHS PRODIGY Guidance FDA on Mibefradil CDC on Mibefradil
Books
Books on Mibefradil
News
Mibefradil in the news Be alerted to news on Mibefradil News trends on Mibefradil
Commentary
Blogs on Mibefradil
Definitions
Definitions of Mibefradil
Patient Resources / Community
Patient resources on Mibefradil Discussion groups on Mibefradil Patient Handouts on Mibefradil Directions to Hospitals Treating Mibefradil Risk calculators and risk factors for Mibefradil
Healthcare Provider Resources
Symptoms of Mibefradil Causes & Risk Factors for Mibefradil Diagnostic studies for Mibefradil Treatment of Mibefradil
Continuing Medical Education (CME)
CME Programs on Mibefradil
International
Mibefradil en Espanol Mibefradil en Francais
Business
Mibefradil in the Marketplace Patents on Mibefradil
Experimental / Informatics
List of terms related to Mibefradil

Mibefradil
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a607007
Routes of; administration	Oral
ATC code	C08CX01 (WHO) ;
Legal status
Legal status	Withdrawn from market;
Pharmacokinetic data
Bioavailability	70 %
Protein binding	> 99 %
Metabolism	Hepatic
Elimination half-life	17-25 h
Identifiers
	IUPAC name (1S,2S)-2-(2-((3-(1H-benzo[d]imidazol-2-yl)propyl) (methyl)amino)ethyl)-6-fluoro-1-isopropyl- 1,2,3,4-tetrahydronaphthalen-2-yl 2-methoxyacetate;
CAS Number	116644-53-2 ;
PubChem CID	60662;
DrugBank	DB01388 ;
ChemSpider	54673 ;
UNII	27B90X776A;
KEGG	D08217 ;
ChEMBL	ChEMBL45816 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C29H38FN3O3
Molar mass	495.63 g/mol
3D model (JSmol)	Interactive image;
Melting point	128 °C (262.4 °F) (dihydrochloride salt)
	SMILES CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)OC(=O)COC)C=C(C=C2)F;
	InChI InChI=1S/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1 ; Key:HBNPJJILLOYFJU-VMPREFPWSA-N ;
(what is this?) (verify)

VisualWikitext

Latest revision as of 19:24, 8 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mibefradil (Posicor) is a drug for the treatment of hypertension and chronic angina pectoris. It belongs to a group known as calcium channel blockers.

It is nonselective.^[1]

On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. ^[2]

Synthesis

References

↑ Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.
↑ Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html

Template:Membrane transport modulators

[pmid7565636-1] Bezprozvanny I, Tsien RW (September 1995). "Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967)". Mol. Pharmacol. 48 (3): 540–9. PMID 7565636.

[2] Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html

[1]

[2]

@@ Line 1: / Line 1: @@
-{{CMG}},{{SS}}
 {{Drugbox
 | Verifiedfields = changed
@@ Line 19: / Line 15: @@
 <!--Pharmacokinetic data-->
-| bioavailability =
+| bioavailability = 70 %
-| metabolism =
+| protein_bound = > 99 %
-| elimination_half-life =
+| metabolism = [[Hepatic]]
+| elimination_half-life =  17-25 h
 | excretion =
@@ Line 52: / Line 49: @@
 | StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
 | StdInChIKey       = HBNPJJILLOYFJU-VMPREFPWSA-N
+| melting_point = 128
+| melting_notes = (dihydrochloride salt)
 }}
+__NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
+'''Mibefradil''' ('''Posicor''') is a drug for the treatment of [[hypertension]] and chronic [[angina pectoris]].  It belongs to a group known as [[calcium channel blockers]].
-'''Mibefradil''' ('''Posicor''') is a drug for the treatment of [[hypertension]] and chronic [[angina pectoris]].  It belongs to a group known as [[calcium channel blockers]].
 It is nonselective.<ref name="pmid7565636">{{cite journal |author=Bezprozvanny I, Tsien RW |title=Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967) |journal=Mol. Pharmacol. |volume=48 |issue=3 |pages=540–9 |date=September 1995 |pmid=7565636 |doi= |url=http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=7565636}}</ref>
 On June 8, 1998, [[Hoffmann–La Roche|Roche]] announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications. <ref>Heart Drug Withdrawn as Evidence Shows It Could Be Lethal: http://www.nytimes.com/1998/06/09/us/heart-drug-withdrawn-as-evidence-shows-it-could-be-lethal.html </ref>
+==Synthesis==
+[[File:Mibefradil1.png|thumb|600px|center|Mibefradil synthesis]]
 ==References==
+{{Reflist|2}}
-{{Reflist}}
 {{Membrane transport modulators}}
-[[Category:Calcium channel blockers]][[Category:Withdrawn drugs]][[Category:Benzimidazoles]][[Category:Organofluorides]][[Category:Ethers]][[Category:Amines]][[Category:Methyl esters]]
+[[Category:Calcium channel blockers]]
+[[Category:Withdrawn drugs]]
-[[Category: Other selective calcium channel blockers with mainly vascular effects]][[Category: Dihydropyridine derivatives]][[Category: Cardiovascular Drugs]][[Category: Drug]]
+[[Category:Benzimidazoles]]
+[[Category:Organofluorides]]
+[[Category:Ethers]]
+[[Category:Amines]]
+[[Category:Drug]]

Mibefradil: Difference between revisions

Latest revision as of 19:24, 8 April 2015

Overview

Synthesis

References

Navigation menu